Schacterle Amy 4

What Happened Amy Schacterle, Chief Regulatory Officer of Acumen Pharmaceuticals (ABOS), received equity grants on 2026-01-16: 84,600 restricted stock units (RSUs) and a 126,900-share derivative award/option, both granted at $0.00 (i.e., awards rather than purchases). Combined, the grants cover 211,500 contingent shares; the filing reports no cash consideration paid.

Key Details

• Transaction date: 2026-01-16; Form 4 filed 2026-01-21 (filed 5 calendar days after the transaction; Form 4s are generally required within 2 business days).
• RSU grant: 84,600 RSUs @ $0.00 (Footnote F1). Vesting: three equal annual installments commencing one year after the grant date, subject to continued service.
• Derivative/option: 126,900 shares @ $0.00 (Footnote F2). Vesting: 48 equal monthly installments, fully vested on the fourth anniversary, subject to continued service.
• Transaction code: A (award/grant). No sale, purchase, or tax-withholding details reported in the provided excerpt.
• Shares owned after the transaction: not disclosed in the provided filing excerpt.

Context These awards are compensation grants that vest over time; RSUs convert to shares at each vesting date, and the derivative award is subject to monthly vesting. Because these are grants (not open-market purchases or sales), they reflect company compensation practices rather than immediate insider buying or selling activity.